Batracylin (NSC 320846, BAY H 2049), given ip on days 2 and 9 at a dose 400 mg/kg, inhibited tumor growth completely in 80-100% of mice with early-stage colon adenocarcinoma 38. Therapeutic efficacy against this subcutaneously implanted tumor was retained upon oral administration of Batracylin although, compared to ip treatment, larger doses were required. Batracylin also caused regression of advanced (400 mg) colon 38 tumors. Only modest activity was observed for this compound against P388 leukemia, but P388 sublines with acquired resistance to either adriamycin or cisplatin demonstrated collateral sensitivity. Batracylin currently is undergoing toxicological evaluation by NCI prior to clinical trials.

No abstract

No abstract

Transport systems of Leuconostoc mesenteroides differ greatly in the stereochemical specificity exhibited for amino acids and dipeptides. Nongrowing cell suspensions of this organism accumulated D- and L-valine to approximately the same extent, whereas no measurable transport of valine from glycyl-D-valine occurred. In concurrent studies, however, a very high uptake of valine was found from glycyl-L-valine. Stereospecific synthesis of the various radioactive valine dipeptides permitted more extensive studies. No valine transport was found from any of the isomeric forms if D-valine was one of the amino acid moieties. Consistent with these observations, no hydrolysis of any dipeptide by intracellular dipeptidases could be detected when D-valine was a part of the peptide. This difference in stereochemical specificity supports the concept of separate transport sites for amino acids and related dipeptides.

No abstract